Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $44 |
| Gross Profit | $0 | $0 | $0 | -$44 |
| % Margin | – | – | – | – |
| R&D Expenses | $21,968 | $37,125 | $25,266 | $34,569 |
| G&A Expenses | $0 | $4,625 | $5,104 | $5,028 |
| SG&A Expenses | $4,545 | $4,625 | $5,104 | $5,028 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,513 | $41,750 | $30,370 | $39,553 |
| Operating Income | -$26,513 | -$41,750 | -$30,370 | -$39,597 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $62 | $800 | $1,574 | $2,443 |
| Pre-Tax Income | -$26,451 | -$40,950 | -$28,796 | -$37,154 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,451 | -$40,950 | -$28,796 | -$37,154 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.68 | -0.48 | -0.62 |
| % Growth | 35.3% | -41.7% | 22.6% | – |
| EPS Diluted | -0.44 | -0.68 | -0.48 | -0.62 |
| Weighted Avg Shares Out | 60,573 | 60,573 | 60,526 | 60,013 |
| Weighted Avg Shares Out Dil | 60,573 | 60,573 | 60,526 | 60,013 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,639 | $2,015 | $2,471 | $2,992 |
| Interest Expense | $1,068 | $1,046 | $1,023 | $1,037 |
| Depreciation & Amortization | $0 | $47 | $45 | $44 |
| EBITDA | -$25,383 | -$39,857 | -$27,728 | -$36,073 |
| % Margin | – | – | – | – |